Medtronic received information via literature regarding a comparison of the early outcomes in patients who underwent tricuspid valve annuloplasty with a tri-ad ring or an mc3 ring.All data were retrospectively collected from a single center between january 2007 and march 2017.The study population included 229 patients and was predominantly male with a mean age of 59 years.Of those, 36 were implanted with medtronic tri-ad annuloplasty rings.No serial numbers were provided.Among all tri-ad patients, one operative death occurred due to unidentified bleeding and hypovolemic shock.Based on the available information, medtronic product may have been associated with the death.Among all tri-ad patients, adverse events included: reoperation due to bleeding, low cardiac output syndrome, stroke, atrial fibrillation, moderate-severe pulmonary hypertension, mild-moderate-severe tricuspid regurgitation, and moderate-severe left ventricle dysfunction (left ventricular ejection fraction less than 40%).Based on the available information, medtronic product was associated with the adverse events.No additional adverse patient effects or product performance issues were reported.
|